In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FoxHollow: Reviving Atherectomy

Executive Summary

The ideal treatment for coronary artery disease is to remove the obstructing plaque, for which several de-bulking technologies, including atherectomy, were developed. The stent revolution of the mid-1990s provided an easier-to-use therapy with more consistent outcomes, relegating de-bulking tools to niche technologies. Physician/entrepreneur John Simpson, who developed the initial atherectomy technology at Devices for Vascular Intervention, remains committed to the principle that it is better to remove plaque than stent it. He believes the next-generation atherectomy device developed at his new company, Fox Hollow, will be a viable treatment option to compete with stenting, including the new generation of drug-eluting stents. Fox Hollow recognizes the need to fight the atherectomy adoption battle on both the ease-of-use and the clinical outcomes fronts, with the latter being particularly important as interventionalists look increasingly to clinical trials in making their product choices. But drug-eluting stent proponents don't believe it is possible to achieve comparable outcomes.
Advertisement

Related Content

Embolic Protection: Unmet Clinical Need or Unneeded Technology
Carotid Stenting: Trials and Tribulations
The A-List: 2006's Trend-Shaping Series A Financings
FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque
FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque
FoxHollow Makes First Acquisition, Buys Kerberos
FoxHollow Makes First Acquisition, Buys Kerberos
Pathway Medical: Pursuing the Hawk
FoxHollow/Merck R&D Deal: The Value of Plaque
John Simpson: Reluctant Entrepreneur

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel